オプションチェーンは、Rocky Mountain Highの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Rocky Mountain Highの市場センチメントを評価します。.

Rocky Mountain High (OTC:RMHB) 株価情報, オプションチェーン

Rocky Mountain High Brands Inc is a brand management company. RMHB specializes in developing, manufacturing, marketing, and distributing high-quality, health-conscious, cannabidiol and hemp-infused products that span various categories including beverage, food, fitness, skincare, and more. It also markets a naturally high alkaline spring water as part of the company's brand portfolio.

ROCKY MTN HIGH BRAND INC by Rocky Mountain High Brands, Inc.

Rocky Mountain High Brands Inc

Wedbush analyst Yun Zhong maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and raises the price target from $181 to $212.

News

Price Target

Analyst Ratings

ASND

Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $212

Keefe, Bruyette &amp; Woods analyst Bose George maintains Annaly Capital Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>) with a Outperform and raises the price target from $20.15 to $20.5.

Keefe, Bruyette & Woods Maintains Outperform on Annaly Capital Management, Raises Price Target to $20.5

WIIM

TNMG

TNMG stock has given up its prior loss. TNL Mediagene shares were trading lower after the company reported a year-over-year decrease in FY24 EPS results.

Canaccord Genuity analyst David Hynes maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Buy and lowers the price target from $300 to $255.

TEAM

Canaccord Genuity Maintains Buy on Atlassian, Lowers Price Target to $255

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Outperform and maintains $30 price target.

Reiteration

TVTX

Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $30 Price Target

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Midland States Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSBI#NASDAQ">MSBI</a>) with a Market Perform and lowers the price target from $21 to $20.

MSBI

Keefe, Bruyette & Woods Maintains Market Perform on Midland States Bancorp, Lowers Price Target to $20

DeFi Development Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>) ("DeFi Dev Corp" or the "Company") announced today that it will begin trading under its new ticker symbol "DFDV" on the Nasdaq Capital Market, effective at market open on May 5, 2025. The change reflects the Company's previously announced corporate name change, deemed market effective by Nasdaq from May 5, 2025, and declared effective as of April 17, 2025 (as previously disclosed), and its strategic shift toward a crypto-forward treasury model anchored in Solana (SOL).
As of May 5, 2025, all Company stock trading, filings, and market related information will be reported under the new symbol "DFDV". The Company's CUSIP number will remain unchanged, and no action is required from shareholders. No other aspects of the Company's corporate structure or operations are impacted by the ticker symbol change.

JNVR

DeFi Development Corp. Announces Ticker Symbol Change To "DFDV", Effective At Market Open On May 5, 2025

Canaccord Genuity analyst Jason Tilchen maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Buy and raises the price target from $80 to $84.

RBLX

Canaccord Genuity Maintains Buy on Roblox, Raises Price Target to $84

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Outperform and raises the price target from $129 to $131.

Keefe, Bruyette & Woods Maintains Outperform on KKR, Raises Price Target to $131

Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $394 to $420.

MDGL

Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $420

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 15 years by 5.76% on an annualized basis producing an average annual return of 16.88%. Currently, Blackstone has a market capitalization of $105.69 billion. 
Buying $1000 In BX: If an investor had bought $1000 of BX stock 15 years ago, it would be worth $11,233.77 today based on a price of $136.72 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746200725_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Wedbush analyst Daniel Ives maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and raises the price target from $250 to $270.

AAPL

Wedbush Maintains Outperform on Apple, Raises Price Target to $270

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) with a Outperform and raises the price target from $183 to $189.

Keefe, Bruyette & Woods Maintains Outperform on Intercontinental Exchange, Raises Price Target to $189

Wedbush analyst Scott Devitt downgrades Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Outperform to Neutral and lowers the price target from $150 to $135.

Downgrades

ABNB

Wedbush Downgrades Airbnb to Neutral, Lowers Price Target to $135

Canaccord Genuity analyst William Plovanic maintains iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) with a Buy and lowers the price target from $152 to $139.

IRTC

Canaccord Genuity Maintains Buy on iRhythm Technologies, Lowers Price Target to $139

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains First Commonwealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCF#NYSE">FCF</a>) with a Market Perform and lowers the price target from $19 to $18.

Keefe, Bruyette & Woods Maintains Market Perform on First Commonwealth, Lowers Price Target to $18

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) with a Market Perform and raises the price target from $307 to $315.

Keefe, Bruyette & Woods Maintains Market Perform on Arthur J. Gallagher, Raises Price Target to $315

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $103 to $106.

DXCM

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $106

PPIH

Perma-Pipe International Holdings shares are trading higher after the company reported a year-over-year increase in Q4 sales results.

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $265 to $220.

Comments

Rocky Mountain High

Rocky Mountain High (RMHB) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル